JPJudit Peix

Judit Peix

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Judit Peix has a total of 106 co-authors. Here are the top co-authors by number of shared publications:

  • Josep Maria Llovet

    Liver Cancer Translational Research Group — IDIBAPS, Liver Unit — Hospital Clínic, Universitat de Barcelona, Barcelona, Spain

    16 shared publications
  • Daniela Sia

    Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Liver Cancer Program, Icahn School of Medicine at Mount Sinai, New York, New York, USA

    14 shared publications
  • Jordi Abril-Fornaguera

    Liver Cancer Translational Research Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain

    14 shared publications
  • Roser Pinyol

    Liver Cancer Translational Research Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain

    13 shared publications
  • Ugne Balaseviciute

    Liver Cancer Translational Research Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain

    13 shared publications
  • Ernesto Guccione

    Center of OncoGenomics and Innovative Therapeutics (COGIT), Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

    11 shared publications

Latest Publications

  • Open Access

    Supplementary Data 1 from E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma

    by Agavni Mesropian, Albert Gris-Oliver, Ugne Balaseviciute, Alka A. Potdar, Takayuki Kimura, Jialing Shen, Martí Torres-Marcén, Jordi Abril-Fornaguera, Marta Piqué-Gili, David Camell-Raventos, et al.

  • Open Access

    Supplementary Data from Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma

    by Jordi Abril-Fornaguera, Laura Torrens, Carmen Andreu-Oller, Juan Carrillo-Reixach, Alex Rialdi, Ugne Balaseviciute, Roser Pinyol, Carla Montironi, Philipp K. Haber, Álvaro Del Río-Álvarez, et al.

    Supplementary Figures and Tables

  • Open Access

    E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma

    by Agavni Mesropian, Albert Gris-Oliver, Ugne Balaseviciute, Alka A. Potdar, Takayuki Kimura, Jialing Shen, Martí Torres-Marcén, Jordi Abril-Fornaguera, Marta Piqué-Gili, David Camell-Raventos, et al.

    Purpose: Aberrant activation of β-catenin (CTNNB1) occurs in ∼30% of hepatocellular carcinomas (HCC) and is associated with immune evasion and limited response to immunotherapy. However, it remains an undruggable target. In this study, we studied the antitumor and antiangiogenic activity of combining E7386 [an oral protein–protein interaction inhibitor targeting CREB-binding protein (CBP)/β-catenin] with lenvatinib and elucidated a novel mechanism of action of E7386 that boosts the antitumor response. Experimental Design: We generated a genetically engineered CTNNB1-mutant murine HCC model and randomized the animals to receive vehicle, E7386, lenvatinib, or the combination (n = 22–23/arm). We evaluated survival and analyzed the tumors transcriptomically and by IHC. Also, we analyzed five patient-derived organoids, four HCC cell lines, and seven paired pre-/on-treatment specimens from patients with HCC receiving E7386 in combination with lenvatinib in the context of a phase Ib/II trial (NCT04008797). Results: E7386 in combination with lenvatinib significantly prolonged mouse survival compared with monotherapy. Cell lines and patient-derived organoid data corroborated that sensitivity to E7386 involves processes beyond CBP/β-catenin interaction blockade. Mechanistically, E7386 promoted activating transcription factor 4 (ATF4) activation, triggering the integrated stress response in preclinical models of HCC. In vivo, E7386 concomitantly potentiated the antiangiogenic effects of lenvatinib, resulting in increased antitumor efficacy. Upregulation of ATF4 gene expression signatures was confirmed in four of seven E7386 + lenvatinib–treated patients with HCC, three of whom exhibited tumor diameter shrinkage >30%. Conclusions: E7386 sensitized tumors to lenvatinib, thereby enhancing survival in mice compared with either monotherapy. In patients, E7386 combined with lenvatinib promoted tumor shrinkage and, in parallel, activated ATF4 signaling.


  • Top Cited Papers
    Open Access

    Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

    by Sarah Cappuyns, Marta Piqué-Gili, Roger Esteban-Fabró, Gino Philips, Ugne Balaseviciute, Roser Pinyol, Albert Gris-Oliver, Vincent Vandecaveye, Jordi Abril-Fornaguera, Carla Montironi, et al.


  • Open Access

    Supplementary Data from Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma

    by Jordi Abril-Fornaguera, Laura Torrens, Carmen Andreu-Oller, Juan Carrillo-Reixach, Alex Rialdi, Ugne Balaseviciute, Roser Pinyol, Carla Montironi, Philipp K. Haber, Álvaro Del Río-Álvarez, et al.

    Supplementary Figures and Tables

  • Open Access

    Supplementary Data from Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma

    by Jordi Abril-Fornaguera, Laura Torrens, Carmen Andreu-Oller, Juan Carrillo-Reixach, Alex Rialdi, Ugne Balaseviciute, Roser Pinyol, Carla Montironi, Philipp K. Haber, Álvaro Del Río-Álvarez, et al.

    Supplementary Figures and Tables

  • Open Access

    Data from Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma

    by Jordi Abril-Fornaguera, Laura Torrens, Carmen Andreu-Oller, Juan Carrillo-Reixach, Alex Rialdi, Ugne Balaseviciute, Roser Pinyol, Carla Montironi, Philipp K. Haber, Álvaro Del Río-Álvarez, et al.

    Management of hepatoblastoma (HB), the most frequent pediatric liver cancer, is based on surgical resection and perioperative chemotherapy regimens. In this study, we aimed to identify actionable targets in HB and assess the efficacy of molecular therapies in preclinical models of HB. Paired tumor and adjacent tissues from 31 HBs and a validation set of 50 HBs were analyzed using RNA-seq, SNP, and methylation arrays. IGF2 overexpression was identified as the top targetable HB driver, present in 71% of HBs (22/31). IGF2high tumors displayed progenitor cell features and shorter recurrence-free survival. IGF2 overexpression was associated in 91% of cases with fetal promoter hypomethylation, ICR1 deregulation, 11p15.5 loss of heterozygosity or miR483-5p overexpression. The antitumor effect of xentuzumab (a monoclonal antibody targeting IGF1/2) alone or in combination with the conventional therapeutic agent cisplatin was assessed in HB cell lines, in PDX-derived HB organoids and in a xenograft HB murine model. The combination of xentuzumab with cisplatin showed strong synergistic antitumor effects in organoids and in IGF2high cell lines. In mice (n = 55), the combination induced a significant decrease in tumor volume and improved survival compared with cisplatin alone. These results suggest that IGF2 is an HB actionable driver and that, in preclinical models of HB, the combination of IGF1/2 inhibition with cisplatin induces superior antitumor effects than cisplatin monotherapy. Overall, our study provides a rationale for testing IGF2 inhibitors in combination with cisplatin in HB patients with IGF2 overexpression.

  • Open Access

    Data from Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma

    by Jordi Abril-Fornaguera, Laura Torrens, Carmen Andreu-Oller, Juan Carrillo-Reixach, Alex Rialdi, Ugne Balaseviciute, Roser Pinyol, Carla Montironi, Philipp K. Haber, Álvaro Del Río-Álvarez, et al.

    Management of hepatoblastoma (HB), the most frequent pediatric liver cancer, is based on surgical resection and perioperative chemotherapy regimens. In this study, we aimed to identify actionable targets in HB and assess the efficacy of molecular therapies in preclinical models of HB. Paired tumor and adjacent tissues from 31 HBs and a validation set of 50 HBs were analyzed using RNA-seq, SNP, and methylation arrays. IGF2 overexpression was identified as the top targetable HB driver, present in 71% of HBs (22/31). IGF2high tumors displayed progenitor cell features and shorter recurrence-free survival. IGF2 overexpression was associated in 91% of cases with fetal promoter hypomethylation, ICR1 deregulation, 11p15.5 loss of heterozygosity or miR483-5p overexpression. The antitumor effect of xentuzumab (a monoclonal antibody targeting IGF1/2) alone or in combination with the conventional therapeutic agent cisplatin was assessed in HB cell lines, in PDX-derived HB organoids and in a xenograft HB murine model. The combination of xentuzumab with cisplatin showed strong synergistic antitumor effects in organoids and in IGF2high cell lines. In mice (n = 55), the combination induced a significant decrease in tumor volume and improved survival compared with cisplatin alone. These results suggest that IGF2 is an HB actionable driver and that, in preclinical models of HB, the combination of IGF1/2 inhibition with cisplatin induces superior antitumor effects than cisplatin monotherapy. Overall, our study provides a rationale for testing IGF2 inhibitors in combination with cisplatin in HB patients with IGF2 overexpression.

  • Open Access

    Data from Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma

    by Jordi Abril-Fornaguera, Laura Torrens, Carmen Andreu-Oller, Juan Carrillo-Reixach, Alex Rialdi, Ugne Balaseviciute, Roser Pinyol, Carla Montironi, Philipp K. Haber, Álvaro Del Río-Álvarez, et al.

    Management of hepatoblastoma (HB), the most frequent pediatric liver cancer, is based on surgical resection and perioperative chemotherapy regimens. In this study, we aimed to identify actionable targets in HB and assess the efficacy of molecular therapies in preclinical models of HB. Paired tumor and adjacent tissues from 31 HBs and a validation set of 50 HBs were analyzed using RNA-seq, SNP, and methylation arrays. IGF2 overexpression was identified as the top targetable HB driver, present in 71% of HBs (22/31). IGF2high tumors displayed progenitor cell features and shorter recurrence-free survival. IGF2 overexpression was associated in 91% of cases with fetal promoter hypomethylation, ICR1 deregulation, 11p15.5 loss of heterozygosity or miR483-5p overexpression. The antitumor effect of xentuzumab (a monoclonal antibody targeting IGF1/2) alone or in combination with the conventional therapeutic agent cisplatin was assessed in HB cell lines, in PDX-derived HB organoids and in a xenograft HB murine model. The combination of xentuzumab with cisplatin showed strong synergistic antitumor effects in organoids and in IGF2high cell lines. In mice (n = 55), the combination induced a significant decrease in tumor volume and improved survival compared with cisplatin alone. These results suggest that IGF2 is an HB actionable driver and that, in preclinical models of HB, the combination of IGF1/2 inhibition with cisplatin induces superior antitumor effects than cisplatin monotherapy. Overall, our study provides a rationale for testing IGF2 inhibitors in combination with cisplatin in HB patients with IGF2 overexpression.

  • Open Access

    Supplementary Data from Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma

    by Jordi Abril-Fornaguera, Laura Torrens, Carmen Andreu-Oller, Juan Carrillo-Reixach, Alex Rialdi, Ugne Balaseviciute, Roser Pinyol, Carla Montironi, Philipp K. Haber, Álvaro Del Río-Álvarez, et al.

    Supplementary Figures and Tables